<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946138</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-HCC2016-02</org_study_id>
    <nct_id>NCT02946138</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma</brief_title>
  <official_title>A Prospective Phase II Single-institution Trial of Carbon-ion Radiotherapy Combined With Granulocyte-macrophage Colony-stimulating Factor for the Treatment of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research project is to assess the efficacy and toxicity of hypofractionated
      carbon-ion radiotherapy with concurrent granulocyte-macrophage colony-stimulating factor for
      the treatment of hepatocellular carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Golden E.B. et al.in 2015 reported that localized radiotherapy granulocyte-macrophage
      colony-stimulating factor (GM-CSF) produced objective abscopal responses in solid tumor with
      metastasises. We hypothesize that hypofractionated carbon-ion radiotherapy combining
      granulocyte-macrophage colony-stimulating factor (GM-CSF) might improve the clinical response
      rate and progression-free survival (PFS) in hepatocellular carcinoma. The primary endpoint of
      the current phase II trial is progression-free survival rate at 2 years, secondary endpoints
      are overall survival, safety and toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival of all patients</measure>
    <time_frame>2 year</time_frame>
    <description>Time in months measured from treatment initiation until the date of progression or the date of last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 year</time_frame>
    <description>Time in months measured from treatment initiation until the date of death or the date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Time interval from the start of carbon-ion radiotherapy to 3 months after the completion of carbon-ion radiotherapy]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective responses rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>carbon-ion radiotherapy with GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gray(Gy) [relative biological effectiveness (RBE)] in 5 fractions for intrahepatic cases away from gastro-intestinal (GI) tract (&gt;1cm) with concurrent GM-CSF 125ug/m2/d, subcutaneous injection d1-28;</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>carbon-ion radiotherapy</intervention_name>
    <description>Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions</description>
    <arm_group_label>carbon-ion radiotherapy with GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically confirmed hepatocellular carcinoma (HCC) or clinical diagnosis of HCC
             according to American association for the study of liver diseases （AASLD）-guidelines
             or clinical diagnosis criteria based on Alpha Fetoprotein （AFP), and radiological
             images proposed by Liver Cancer Society, Chinese Anti-Cancer Association;

          2. no clinically distant metastasis;

          3. the tumor is away from gastro-intestinal (GI) tract (&gt;1cm);

          4. Child Push score A,technically unresectable, or medically inoperable; maximal tumor
             size is less than 10 cm;

          5. age ≥ 18 and &lt;80 years of age;

          6. Karnofsky Performance Score ≥ 70;

          7. No previous invasive cancer (within 5 years before the HCC diagnosis)except for skin
             non-melanoma cancer or non muscle invasive bladder cancer; Ability to understand
             character and individual consequences of the clinical trial;

          8. Willing to sign the written informed consent; Informed consent must be signed before
             the enrollment in the trial;

        Exclusion Criteria:

          1. Distant metastasis (M1);

          2. maximal tumor size is more than 10 cm;

          3. tumor invading adjacent gastrointestine (T4);

          4. Child push score B or C;

          5. Previous hepatic radiotherapy;

          6. Severe systemic disorders;

          7. Previous malignancy (within 5 years) except for skin non-melanoma cancer or 3-year
             disease free interval from previous malignancy like in situ cervix cancer or non
             muscle invasive bladder cancer;

          8. Non conformity of the radiotherapy dose distribution when compared to the dose
             constraints;

          9. Psychiatric disorders or any other condition that can make unreliable the informed
             consent;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>guo-liang jiang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Wang, Dr.</last_name>
    <phone>+86-021-38296666</phone>
    <phone_ext>53609</phone_ext>
    <email>zheng.wang@sphic.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei-xiang Qi, Dr.</last_name>
    <email>weixiang.qi@sphic.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201321</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zheng wang, MD</last_name>
      <phone>+86-021-38296666-53609</phone>
      <email>zheng.wang@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>weixiang Qi, MD</last_name>
      <phone>+86-021-38296666-53609</phone>
      <email>weixiang.qi@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>guoliang Jiang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <zip>201321</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zheng wang, MD</last_name>
      <phone>+86-021-38296666-53609</phone>
      <email>zheng.wang@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>weixiang Qi, MD</last_name>
      <phone>+86-021-38296666-53609</phone>
      <email>weixiang.qi@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>guoliang Jiang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Guoliang Jiang</investigator_full_name>
    <investigator_title>Director the committee of clinical technique</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>carbon-ion radiotherapy</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

